Physician profile
Mark Carey
NPI 1003835422
$1,311.48
in general payments reported to CMS, 2019-2025
20 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $134 · 2021: $134 · 2022: $35.31 · 2023: $73.36 · 2024: $194 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $293.13 | 2019-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $159.40 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $152.80 | 2022-2024 | |
| Daiichi Sankyo INC. | $139.11 | 2019-2023 | Injectafer |
| Radius Health, INC. | $124.29 | 2019-2020 | |
| Vifor Pharma, INC. | $66.25 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $53.96 | 2019 | |
| Allergan, INC. | $47.39 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $43.66 | 2019 | |
| Opko Pharmaceuticals, LLC | $32.01 | 2019 | |
| Travere Therapeutics, INC. | $29.34 | 2020-2024 | |
| Ascendis Pharma Endocrinology INC | $27.41 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $26.16 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.72 | 2025 | Voyxact |
| Medtronic, INC. | $18.64 | 2023 | Ellipsys Vascular Access System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2022 | |
| Shire North American Group INC | $15.77 | 2019 | |
| Aurinia Pharma U.S., INC. | $15.00 | 2021 | |
| Akebia Therapeutics INC | $13.79 | 2019 | |
| Horizon Therapeutics Plc | $11.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.